How to distinguish healthy from diseased? Classification strategy for mass spectrometry-based clinical proteomics-Reference-Cited by-同舟云学术

How to distinguish healthy from diseased? Classification strategy for mass spectrometry-based clinical proteomics

Published:2007-09-19 Issue:20 Volume:7 Page:3672-3680
ISSN:1615-9853
Container-title:PROTEOMICS
language:en
Short-container-title:Proteomics

Author:

Hendriks Margriet M. W. B.,Smit Suzanne,Akkermans Wies L. M. W.,Reijmers Theo H.,Eilers Paul H. C.,Hoefsloot Huub C. J.,Rubingh Carina M.,de Koster Chris G.,Aerts Johannes M.,Smilde Age K.

Publisher

Wiley

Subject

Molecular Biology,Biochemistry

Reference33 articles.

1. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments

2. Prediction of cancer outcome with microarrays: a multiple random validation strategy

3. Comparison of statistical methods for classification of ovarian cancer using mass spectrometry data

4. Computational protein biomarker prediction: a case study for prostate cancer

5. Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elp3‐mediated codon‐dependent translation promotes mTORC2 activation and regulates macrophage polarization;The EMBO Journal;2022-08-03

2. Mass spectrometry-based proteomics in neurodegenerative lysosomal storage disorders;Molecular Omics;2022

3. The E3 ligase COP1 promotes ERα signaling and suppresses EMT in breast cancer;Oncogene;2021-10-29

4. Untargeted fecal metabolomics revealed biochemical mechanisms of the blood lipid-lowering effect of koumiss treatment in patients with hyperlipidemia;Journal of Functional Foods;2021-03

5. A random forest based biomarker discovery and power analysis framework for diagnostics research;BMC Medical Genomics;2020-11-23